Our previous study found that the allergy mediator histamine could suppress tumor growth, and induce immunotherapy resistance via binding to histamine receptor H1 on macrophages, and anti-histamine therapy could synergistically enhance efficacy of ICB therapy [26]. Here, HRH1 is linked to allergic disease.